Phase 1a/1b Open-Label Study of IGM-8444 Monotherapy and Combination Therapy in Relapsed, Refractory, or Newly Diagnosed Colorectal Cancer

The primary objective of this study is to evaluate the safety and tolerability of **IGM-8444** as a single agent and in combination with other treatments in subjects with relapsed, refractory, or newly diagnosed **colorectal cancer**. This is clinically relevant as it aims to determine the potential of IGM-8444 to provide a new therapeutic option for patients with limited treatment alternatives. The study does not specify any secondary objectives.

The clinical trial involves a total of **408 participants** diagnosed with **colorectal cancer**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided by the sponsor. The general health status of the participants is not detailed, nor are any lifestyle considerations such as diet, physical activity, or habits. The trial aims to encompass a diverse demographic to ensure comprehensive data collection and analysis.

The clinical trial is designed as an open-label, multicenter, Phase 1a/1b study to evaluate the investigational agent **IGM-8444** as a single agent and in combination with other treatments in subjects with relapsed, refractory, or newly diagnosed **colorectal cancer**. The trial is set to commence recruitment on December 1, 2023, and is anticipated to conclude by November 1, 2026. The study will involve a series of structured visits, beginning with an inclusion visit where participants will undergo screening to confirm eligibility based on predefined criteria. This initial visit will include assessments such as medical history review, physical examination, and laboratory tests to ensure compliance with the study's inclusion and exclusion criteria.

Following the inclusion visit, participants will be enrolled in the trial and randomized to receive the investigational treatment. The trial design does not incorporate blinding or a control group, as it is an open-label study. Participants will attend regular follow-up visits at specified intervals to monitor safety, tolerability, and preliminary efficacy of the treatment. These visits will include clinical evaluations, laboratory tests, and imaging studies as necessary. The frequency and specific procedures of follow-up visits will be determined by the study protocol and may vary depending on the phase of the trial and the treatment regimen.

The end-of-study visit will mark the completion of the participant's involvement in the trial. During this visit, final assessments will be conducted to evaluate the overall outcomes and any long-term effects of the treatment. The expected duration of participant involvement will vary, but it is anticipated to align with the overall trial timeline, unless early termination is warranted. Conditions that may lead to early termination from the study include adverse events, withdrawal of consent, or any other protocol-specified criteria. Participants will be closely monitored throughout the study to ensure their safety and well-being, with any necessary adjustments made to the treatment plan as required.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the lack of specific data, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be detailed. The absence of this information precludes the provision of a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of December 1, 2023, and an estimated end date of November 1, 2026. Although specific efficacy parameters or endpoints are not detailed, Phase 1 trials typically focus on safety and dosage, with preliminary assessments of efficacy. The methods for measuring, collecting, and analyzing efficacy data are not specified, but such trials often involve the use of validated scales, laboratory tests, and patient-reported outcomes. The schedule for these assessments is not provided, but they are generally conducted at multiple timepoints throughout the trial to monitor changes and trends. The trial's primary focus is to gather initial data on the investigational product's effects, which will inform subsequent phases of clinical research.